EDITORIAL SECTION
-
STRATEGY
Strategic Positioning for M&A
The biotechnology sector is characterised by a constant influx of small highly specialised companies
-
RESEARCH DEVELOPMENT
Cytiva Laboratory capsule filters
Our singleuse selfcontained filtration solutions help reduce contamination risk and lower manual handling
-
CLINICAL TRIALS
Virtual Clinical Trials
Virtual digital and decentralized are all descriptions of the novel ways that using technology changes
-
Bio Pharma
Biosimilars and Biobetters
Biosimilars are biologic medical products that are essentially identical to an original product manufactured
-
MANUFACTURING
Transformative Convergence of AI in Pharmaceutical Manufacturing
The pharmaceutical manufacturing industry is on the cusp of a revolutionary transformation driven by
-
Information Technology
Transformative Impact of Artificial Intelligence on Clinical Trials
Artificial Intelligence AI has rapidly evolved from a futuristic concept to a transformative tool across various industries
-
EXPERT Talk
Pharma's Medical Affairs Bridge: From Field Insights and Stakeholder Needs to Global Scientific Strategy
Medical Affairs has evolved from being primarily a supportive and educational function to becoming a strong strategic partner earlier on Through ongoi...
Advisory Board
.webp "Juris Hmelnickis")
.webp "Eiman Shafa")
KNOWLEDGE BANK
-
Articles
U.S. Pharmaceutical Intellectual Property Strategy: Patents, Exclusivity and Competitive Protection
Bringing a new drug to market can cost over a billion dollars and take a decade or more Copying that drug can cost a tiny fraction of that Without legal protection no company could recover its investment and fewer new medicines would reach patients
-
Techno Trends
Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment
Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment
-
Projects
Genentech Begins US$750 Million Expansion of Oregon Manufacturing Facility
Genentech a member of the Roche Group has started construction on a US million expansion of its manufacturing facility in Hillsboro Oregon The squarefoot project will double the existing sites footprint and increase US production capacity for advanced drug delivery devices
-
Research Insights
Identification of flavonoids from natural products against hyperlipidaemia through computational approaches
Over the centuries hyperlipidaemia has been recognised as a major risk factor contributing to cardiovascular disease CVD Current research increasingly explores natural compounds such as flavonoids for their potential lipidlowering effects This study evaluated pharmacological potential
-
White Papers
Post-Translational Modifications in Drug Discovery: From Molecular Regulation to Clinical Impact
For decades the central dogma of molecular biology has anchored our understanding of cellular function DNA to RNA to protein But this linear view is incomplete A growing body of evidence shows that much of biologys complexity
TOP ARTICLES
-
1
Solutions from Technology to Innovation: Transforming Pharmaceutical Production in North America
Kate Williamson
The integration of technology is reshaping pharmaceutical production in North America, with automation, data analytics, 3D printing, regulatory compliance tools, blockchain, and remote monitoring play...
-
2
New Drug Development and Clinical Trial Design by Applying Genomic Information Management
Jeong-An Gim
Young Kyung Ko
Depending on the patients’ genotype, the same drug may have different efficacies or side effects. With the cost of genomic analysis decreasing and reliability of analysis methods improving, vast...
-
3
10 Reasons to Consider Placebo Use in Clinical Trials
Kate Williamson
Clinical trials are pivotal for medical advancements, and the use of placebos is a critical element. This exploration outlines ten reasons for the essential role of placebos, emphasizing their contrib...
-
4
Applying CPCA: A Risk Based Framework for Nitrosamine Control in Pharmaceuticals
Subathra Ramamoorthy
As nitrosamine control shifts from reactive testing to a lifecycle, risk based obligation, the Carcinogenic Potency Categorization Approach (CPCA) has emerged as a critical regulatory tool. This arti...
-
5
What Is Driving Investment in Cell and Gene Therapy Manufacturing in the US
Lakshmi
Cell and gene therapy has moved from scientific promise to industrial reality in the United States, and manufacturing has become the decisive battleground. Regulatory reforms easing manufacturing expe...
press releasesRead more...
Scipher Medicine Launches PrismTcell™, the Next Molecular Treatment Response Signature, for Abatacept in Rheumatoid Arthritis
Scipher Medicine Scipher a leader in immunology precision medicine today announced the expected launch of an early physician access program for PrismTcell its new Molecular Treatment Response Signature MTRS for abatacept PrismTcell is a bloodbased test designed to predict response to abatacept
Alume Biosciences Announces FDA Acceptance of New Drug Application for Bevonescein for Use During Surgery
Alume Biosciences today announced that the US Food and Drug Administration FDA has accepted for filing and review the companys New Drug Application NDA for bevonescein ALM an investigational fluorescent drug intended to help surgeons visualize nerves
Egetis Therapeutics Announces U.S. Launch of EMCITATE® for Patients with MCT8 Deficiency
Egetis Therapeutics AB a commercialstage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases today announced the commercial availability of EMCITATE tiratricol ahead of anticipated timelines following US Food and Drug Administration FDA ap...
Rumi Therapeutics Announces Licensing Agreement With Enthorin Therapeutics to Advance RTX-7340, an IND-Ready PDE2 Inhibitor, for Fragile X Syndrome
Rumi Therapeutics a drugdevelopment company within Rumi Scientific Holdings today announced an option to license agreement with Enthorin Therapeutics to advance RTX ENT an investigational phosphodiesterase PDE inhibitor for the treatment of Fragile X syndrome FXS The agreement brings an INDready th...
Events Read more...
28 - 30
Oct 2026BIOPLUS-INTERPHEX Korea
COEX, Seoul
02 - 04
Nov 2026Pharma Forum EMEA 2026
Dom Pedro Lisboa Hotel, Lisbon...
02 - 04
Nov 2026Cancer R&D 2026
Houston, TX, USA
03 - 05
Nov 202610th Dermatology Drug Development
Boston, Massachusetts at The C...
03 - 04
Nov 2026PDA Aseptic Processing of Biopharma Conference
Sheraton Grand Incheon Hotel,...
04 - 05
Nov 2026Advanced Therapies USA
Hynes Convention Center, Bosto...
05 - 05
Nov 2026PDA Contamination Control Strategy Workshop
Sheraton Grand Incheon Hotel,...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
LATEST NEWSRead more...
Rakovina Therapeutics and Celvion Therapeutics Complete AI Analysis Identifying Priority Cancer Indications for Brain-Penetrant ATR Inhibitor Program
Rakovina Therapeutics Inc a biopharmaceutical company advancing innovative cancer therapies through AIpowered drug discovery and Bostonbased Celvion Therapeutics Celvion today announced the completion of the first analysis in their collaboration using Celvions EMphora
Manta Cares and Cancer Support Community SF Bay Area Partner to Bring AI-Powered Cancer Support to Northern California Patients and Families
Manta Cares a San Francisco company that builds AI for people with cancer and their families and Cancer Support Community San Francisco Bay Area CSC SFBA which has offered free support to people affected by cancer since today announced a partnership to offer a new level of support for people
Onco360® Has Been Selected as a National Pharmacy Partner for ZEGFROVY® (sunvozertinib)
Onco the nations leading independent Specialty Pharmacy has been selected as a national pharmacy partner by AstraZeneca Pharmaceuticals for Zegfrovy sunvozertinib which is indicated for the treatment of adult patients with locally advanced or metastatic nonsmall cell lung cancer NSCLC with epidermal...
Octant Receives FDA Orphan Drug Designation for OCT-980 for the Treatment of Retinitis Pigmentosa
Octant Inc Octant a clinicalstage drug discovery company developing correctors for protein misfolding diseases today announced that the US Food and Drug Administration FDA has granted Orphan Drug Designation to OCT for the treatment of retinitis pigmentosa RP The designation includes rhodopsinassoci...
Regeneron Extends Agreement with BARDA to Provide Additional Supply of Ebola Treatment Inmazeb® for U.S. Preparedness
Regeneron Pharmaceuticals Inc announced today that it has extended its agreement with the Biomedical Advanced Research and Development Authority BARDA part of the Administration for Strategic Preparedness and Response ASPR within the US Department of Health and Human Services
Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug Delivery
Aptar Pharma a global leader in drug delivery dosing protection technologies and services today announced the strategic acquisition of PULMOTREE a Munich Germanybased life science company specializing in pulmonary drug delivery systems for targeted delivery to the lungs The acquisition is expected t...
